ReproCell Saham

ReproCell EBITDA

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari ReproCell (4978.T) pada 26 Jul 2026 adalah -111,96 Juta. JPY. Tahun sebelumnya, EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah -393,04 Juta. JPY — perubahan sebesar -71,52% (lebih tinggi).

EBITDA

-111,96 Juta.JPY

YoY

-71,52%

Terakhir Diperbarui:

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari ReproCell adalah 2026 -111,96 Juta. JPY. EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari ReproCell adalah 2025 -393,04 Juta. JPY. Menurun -71,52% lebih tinggi dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

ReproCell Analisis saham

Apa yang dilakukan ReproCell? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham ReproCell

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) ReproCell adalah -111,96 Juta. JPY pada tahun 2026.

Access this data via the Eulerpool API

Laporan Laba Rugi — ReproCell

Semua Metrik Kunci — ReproCell